Close menu




October 1st, 2025 | 07:05 CEST

Almonty Industries, Gerresheimer, BASF – It is not too late yet!

  • Mining
  • Tungsten
  • Defense
  • chemicals
  • Pharma
Photo credits: pixabay.com

The race for critical high-tech goods and raw materials is already underway. The COVID-19 pandemic painfully highlighted the downsides of a globally interconnected economy. China's export ban on critical raw materials is currently having a double impact, as the country dominates the market. This effect is expected to continue to intensify in the future as demand continues to rise dynamically while supply increases only slowly. This provides a strong tailwind for raw material producers, but poses significant challenges for companies in other sectors.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: ALMONTY INDUSTRIES INC. | CA0203987072 , GERRESHEIMER AG | DE000A0LD6E6 , BASF SE NA O.N. | DE000BASF111

Table of contents:


    Almonty Industries – The countdown is on!

    It will only be a few more weeks before the Sandong tungsten mine operated by the Canadian company goes into operation. Tungsten is a critical metal and is characterized by its extreme hardness and the highest melting point of all metals. It is therefore used in industry in the form of (super) alloys. Other uses include filaments, radiation protection, and medical technology. The aerospace and defense industries are also heavily dependent on tungsten.

    The start of production and a further planned expansion stage, which will double output again by 2027, is a real highlight. Not only for shareholders, who have been enjoying strong price increases for some time now, but also from a geopolitical perspective. The Sandong mine will be the largest tungsten producer outside China. It is already crystal clear that the tungsten market will remain in imbalance for many years to come. Demand currently exceeds supply by 5,570 tons. The Canadians have already secured several long-term supply contracts.

    Almonty is advancing a second project on its property in South Korea. A major drilling program was recently launched to update and expand the molybdenum mineralization, with a view to also going into operation in the future. Molybdenum improves the heat resistance of alloys and is used, for example, in electrical engineering.

    The stock is currently trading at an all-time high of around CAD 8.50, corresponding to a market capitalization of CAD 1.9 billion. The stock's strong past performance recently led to its inclusion in the TSX30™ 2025. This is a huge accolade, as it means Almonty is one of the 30 top performers on the Toronto Stock Exchange over the last three years. Strong operational developments and the completed NASDAQ listing have given the share price a considerable boost in recent months. But the journey is far from over!

    Gerresheimer – Analysts see significant upside potential!

    The share price has been hovering around the EUR 35 mark in recent days as it attempts to digest the previous slide. The German Financial Supervisory Authority (BaFin) recently announced that it would be auditing Gerresheimer's consolidated financial statements and management report for the 2024 financial year. There is suspicion that the group booked sales in 2024 that had not yet been realized. This could mean that the packaging manufacturer may have violated applicable accounting regulations.

    Ultimately, however, this "only" accounts for a few percent of the group's total revenue. What remains, however, is investor uncertainty. During the course of the month, the shares even briefly dipped to a 15-year low of around EUR 26.50. Despite this, analysts at Hauck Aufhäuser IB maintained their "Buy" rating and EUR 65 price target. In addition, the planned sale of the molded glass business could provide further positive momentum for the stock, according to the experts.

    BASF – A zero-sum game

    With its four core businesses of Chemicals, Materials, Industrial Solutions, and Nutrition & Care, the Ludwigshafen-based company is heavily dependent on raw materials, commodities, and energy. Price fluctuations in these areas have a significant impact on its margins. Some specialty chemicals require critical raw materials as inputs, putting supply security high on the list of priorities. In addition, the world's largest chemical company is suffering from decarbonization pressures and stringent sustainability requirements.

    The bottom line is that investors have earned nothing from the stock this year, apart from the dividend of EUR 2.25. A few days ago, negative industry commentary from Deutsche Bank caused prices to fall. The bank's expert expects a weak second half of the year and paints a negative picture for the future with increasing risks, a prolonged downturn based on the uncertain trading environment, exchange rate effects, and competitive pressure. According to S&P Global Market Intelligence, a total of 20 analysts assign the stock an average upside potential of 16% over the next 12 months.

    It doesn't always have to be "Either-Or"

    Investing means making choices. Value, growth, stock picking, or investing in an industry trend? Sometimes, however, you do not have to choose just one. With Almonty stock, investors get the best of both worlds: a long-term industry trend plus an outstanding competitive position. The situation at BASF is more complicated because the Company is more vulnerable due to its size and many business areas. Gerresheimer's stock was also exposed, first due to weak operational performance that disappointed investors, and more recently because of uncertainty following the BaFin investigation. However, opportunities are once again outweighing the risks.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST

    BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk

    • Biotechnology
    • Biotech
    • Pharma
    • biosimilars
    • patents

    The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.

    Read

    Commented by Tarik Dede on October 9th, 2026 | 09:10 CEST

    Drones, AI and Gold: Samsung, Volatus Aerospace and Equinox Gold in Focus

    • Drones
    • Defense
    • geopolitics
    • AI
    • Gold
    • Commodities

    These are turbulent times for the stock markets. Interest rates are rising, bank stocks are weakening, and the number of mega-IPOs, including SpaceX and Anthropic, keeps growing. Parallels with previous stock-market crashes are becoming increasingly apparent. Yet many investors are still riding a wave of euphoria. The current bull market is already the longest in US stock-market history, driven largely by artificial intelligence. But the downside is becoming increasingly evident: valuations are high, and concentration in the major stock indices is enormous. Consider just one example: ten stocks, the so-called Magnificent Seven, along with Broadcom, AMD, and Micron, now account for 42% of the S&P 500. At these levels, there is little room for anything to go wrong. Even in this market environment, however, opportunities and risks coexist. Today, we take a closer look at Samsung, Volatus Aerospace and Equinox Gold.

    Read

    Commented by Fabian Lorenz on October 9th, 2026 | 07:30 CEST

    Deutz Stock Under Pressure! Buy Recommendations for Bayer and Partner MustGrow Biologics

    • biologicals
    • biofertilizer
    • biocontrol
    • agritech
    • mustard
    • Pharma

    Created and Published on Behalf of MustGrow Biologics Corp.

    What is going on with Deutz? The Cologne-based company had emerged as a favourite among investors looking to capitalize on the defence boom. But after more than doubling in just a few months, the stock has recently fallen by around 20%. There are clear reasons for the pullback—but should investors be worried? There is certainly reason for optimism at MustGrow. The US commercialization of the soil-fertility product TerraSante™ has begun, and demand is outpacing supply. Contract manufacturers now need to ramp up production quickly. Analysts expect revenues and earnings to rise sharply in the coming years. A partnership with Bayer is also expected to contribute to this growth. Bayer, meanwhile, plans to expand its US presence with a multibillion-dollar investment. The stock is not currently benefiting from this development. Nevertheless, analysts are recommending the shares as a Buy.

    Read